MDxHealth Licenses Biomarkers for Bladder Cancer to Predictive Biosciences
Under the agreement, MDxHealth grants Predictive Biosciences exclusive rights for the use of a number of its DNA methylation biomarkers in bladder cancer testing in the United States. MDxHealth retains exclusive worldwide rights to these markers in tissue-based bladder cancer tests. In return, MDxHealth will receive upfront and milestone payments and royalties on net sales. Predictive Biosciences is one of the few diagnostic companies with a strong focus on applications in urologic oncology, including bladder cancer.
Most read news
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.